Brief: Sab Biotherapeutics Announces Update To The Phase 3 Nih Activ-2 Trial Design Evaluating Sab-185 For Treatment Of Covid-19

SAB Biotherapeutics

25/02/2022 12:39

Feb 25 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS ANNOUNCES UPDATE TO THE PHASE 3 NIH
ACTIV-2
TRIAL DESIGN EVALUATING SAB-185 FOR TREATMENT OF COVID-19
    * SAB BIOTHERAPEUTICS- ADDITIONAL 800 PARTICIPANTS WILL BE
ENROLLED TO SUPPLEMENT ABOUT 400 PARTICIPANTS ALREADY
PARTICIPATING IN SAB-185 PHASE 3 TRIAL
    * SAB BIOTHERAPEUTICS INC-  SAB-185 PHASE 3 TRIAL EXPECTED
TO
RESTART IN COMING WEEKS
    * SAB BIOTHERAPEUTICS INC- PHASE 3 TRIAL DESIGN IS AMENDED
TO
PIVOT TO A BLINDED, RANDOMIZED, PLACEBO-CONTROLLED SUPERIORITY
TRIAL
    * SAB BIOTHERAPEUTICS INC-  PHASE 3 TRIAL STUDY ENDPOINTS
REMAIN
UNCHANGED

Source text for Eikon:  ID:nGNX70pgbv 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;))